文献速递类风湿关节炎

达标后停用甲氨蝶呤对使用生物或靶向合成改善病情抗风湿药联合甲氨蝶呤的类风湿关节炎患者的影响:系统评价与荟萃分析

Withdrawal of MTX in rheumatoid arthritis patients on bDMARD/tsDMARD plus methotrexate at target: a systematic review and meta-analysis.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

该系统评价与荟萃分析纳入6项非劣效随机对照试验共1430例达标类风湿关节炎患者,比较停用或减量甲氨蝶呤与继续联合治疗的效果。停用甲氨蝶呤使DAS28升高0.20(95%CI 0.09, 0.32),DAS28评估的低疾病活动度比例降低(RR 0.88,95%CI 0.80, 0.97),但DAS28、SDAI、CDAI或ACR/EULAR布尔缓解率未显著降低。作者认为停用甲氨蝶呤轻度增加疾病活动度,对深度缓解患者影响有限。

要点

  • 达标后停用甲氨蝶呤使DAS28升高0.20(95%CI 0.09, 0.32),低疾病活动度比例降低(RR 0.88)。
  • 停用甲氨蝶呤未显著降低DAS28、SDAI、CDAI或ACR/EULAR布尔缓解率。
  • 作者认为停用甲氨蝶呤轻度增加疾病活动度,对深度缓解患者影响有限。

核心结论

  • 达标后停用甲氨蝶呤轻度增加使用bDMARD/tsDMARD联合甲氨蝶呤治疗的类风湿关节炎患者的疾病活动度,对深度缓解患者影响有限。

研究设计与样本

  • 系统评价与荟萃分析,检索PubMed、EMBASE和Cochrane CENTRAL数据库从建库至2022年3月7日的随机对照试验,纳入6项非劣效随机对照试验共1430例患者(停用组734例,继续组696例)。
  • 采用Cochrane Q检验和I2检验评估异质性,使用随机效应模型进行数据合成,研究注册于PROSPERO(CRD42022303891)。

主要发现

  • 与继续联合治疗相比,减量或停用甲氨蝶呤使DAS28升高0.20(95%CI 0.09, 0.32,I2=0%)。
  • 停用甲氨蝶呤使DAS28评估的低疾病活动度(<3.2)患者比例降低(RR 0.88,95%CI 0.80, 0.97,I2=0%)。
  • 停用甲氨蝶呤未显著降低DAS28评估的缓解率(RR 0.90,95%CI 0.81, 1.01)。
  • 停用甲氨蝶呤未显著降低SDAI评估的缓解率(RR 0.93,95%CI 0.77, 1.11)。
  • 停用甲氨蝶呤未显著降低CDAI评估的缓解率(RR 0.90,95%CI 0.74, 1.11)或ACR/EULAR布尔缓解率(RR 0.95,95%CI 0.70, 1.29)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the effect of MTX withdrawal on disease activity and remission rate in patients at target after treatment with biologic DMARDs (bDMARDs)/targeted synthetic DMARDs (tsDMARDs) plus MTX. MATERIAL AND METHODS: We searched the PubMed, EMBASE and Cochrane Central Register of Controlled Trials (CENTRAL) databases for all randomized controlled trials (RCTs) on MTX withdrawal in patients with RA at target after combination therapy from inception to 7 March 2022 in order to extract data, including: the change from withdrawal in DAS28 at the endpoint; proportion of low disease activity (LDA) assessed by DAS28, Simplified Disease Activity Index (SDAI) or Clinical Disease Activity Index (CDAI); proportion of remission assessed by DAS28, SDAI CDAI or ACR/EULAR Boolean remission. The Cochrane Q test and I2 test were used to assess heterogeneity, and random-effects models were used for data synthesis. This study is registered with PROSPERO (CRD42022303891). RESULTS: Six articles were included for qualitative and quantitative analysis, all of which were noninferior RCTs involving 1430 patients (734 in the withdrawal group and 696 in the continuation group). Compared with continuing combination therapy, tapering off or discontinuing MTX increased DAS28 by 0.20 (95% CI 0.09, 0.32, I2 = 0%) and decreased the percentage of patients with LDA assessed by DAS28 to <3.2 [risk ratio (RR) 0.88 (0.80, 0.97), I2 = 0%]. However, MTX withdrawal did not decrease remission rates assessed by DAS28, SDAI, CDAI or ACR/EULAR Boolean remission [RR 0.90 (0.81, 1.01), 0.93 (0.77, 1.11), 0.90 (0.74, 1.11), 0.95 (0.70, 1.29), respectively]. CONCLUSIONS: Withdrawing MTX slightly increases the RA disease activity in patients treated at target with bDMARDs/tsDMARDs plus MTX and has limited effects for patients with deep remission.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Wang X, Tang Z, Huang T, et al. Withdrawal of MTX in rheumatoid arthritis patients on bDMARD/tsDMARD plus methotrexate at target: a systematic review and meta-analysis. Rheumatology (Oxford). 2023. PMID: 36125185. doi:10.1093/rheumatology/keac515

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。